May. 13 at 8:59 PM
$CLLS On April 20, 2026, Life Technologies Corporation ("LTC"), a subsidiary of Thermo Fisher, claimed to terminate licensing agreements between LTC and Cellectis in 2014, which grant Cellectis non-exclusive rights under certain patents, namely Halle Patent Therapeutic License, Halle Patent Research License and GeneArt and Seamless Cloning Patent Therapeutic License (the "LTC Agreements"). This alleged termination follows TFS's allegations that we did not comply with our obligations under the LTC Agreements, as previously indicated. Simultaneously, LTC brought arbitration proceedings before the American Arbitration Association, designating Cellectis S.A. and Cellectis Bioresearch, Inc. as defendants. LTC's arbitration request alleges that Cellectis violated the LTC Agreements, by underpaying sub-licensing fees and more generally by not complying with our obligations under the LTC Agreements.
